Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

The ErbB2 (Her2) proto-oncogene encodes a receptor tyrosine kinase, which is frequently amplified and overexpressed in human tumors. ErbB2 provides the target for a novel and effective antibody-based therapy (Trastuzumab/Herceptin) used for the treatment of mammary carcinomas. However, cardiomyopath...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Özcelik, Cemil, Erdmann, Bettina, Pilz, Bernhard, Wettschureck, Nina, Britsch, Stefan, Hübner, Norbert, Chien, Kenneth R., Birchmeier, Carmen, Garratt, Alistair N.
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2002
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC124392/
https://ncbi.nlm.nih.gov/pubmed/12072561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.122249299
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars